Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption

Clinical Cancer Research

Volumn 15, Issue 11, 2009, Pages 3751-3759

  Strube, Anne ^a   Hoffmann, Jens ^a   Stepina, Elizaveta ^a   Hauff, Peter ^a   Klar, Ulrich ^a   Käkönen, Sanna Maria ^a,b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; SAGOPILONE;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; BONE METASTASIS; BREAST CANCER; CACHEXIA; CANCER GROWTH; CANCER INHIBITION; CELL ACTIVATION; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PARAPLEGIA; PRIORITY JOURNAL; QUALITY OF LIFE; SINGLE DRUG DOSE; WEIGHT REDUCTION;

ACID PHOSPHATASE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BENZOTHIAZOLES; BONE AND BONES; BONE NEOPLASMS; BONE RESORPTION; CACHEXIA; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOTHILONES; FEMALE; HUMANS; ISOENZYMES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; OSTEOCLASTS; OSTEOLYSIS; PACLITAXEL; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66649097584     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3123     Document Type: Article

References (40)

1. Hortobagyi GN. Novel approaches to the management of bone metastases in patients with breast cancer. Semin Oncol 2002;29:134-144 (Pubitemid 34816076)
2. Brown JE, Coleman RE. The role of bisphosphonates in breast cancer: the present and future role of bisphosphonates in the management of patients with breast cancer. Breast Cancer Res 2002;4:24-29
3. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-176 (Pubitemid 32452017)
4. Cameron D, Fallon M, Diel I. Ibandronate: its role in metastatic breast cancer. Oncologist 2006;11:27-33.
5. Guise TA, Kozlow WM, Heras-Herzig A, Padalecki SS, Yin JJ, Chirgwin JM. Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer 2005;5:S46-53.
6. Käkönen S-M, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 2003;97:834-839 (Pubitemid 36125820)
7. Lipton A. Future treatment of bone metastases. Clin Cancer Res 2006;12:6305-8s. (Pubitemid 44703808)
8. Horwitz SB. Mechanism of action of taxol. Trends Pharmacol Sci 1992;13:134-136
9. Horwitz SB, Cohen D, Rao S, Ringel I, Shen H-J, Yang C-PH. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr 1993;15:55-61.
10. Kim R, Osaki A, Toge T. Feasibility and therapeutic efficacy of weekly 1-h low-dose paclitaxel infusion for relapsed breast cancer. Oncol Rep 2003;10:145-150
11. Abrams JS, Vena DA, Baltz J, et al. Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial. J Clin Oncol 1995;13:2056-2065
12. Klar U, Buchmann B, Schwede W, Skuballa W, Hoffmann J, Lichtner RB. Total synthesis and anti-tumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development. Angew Chem Int Ed Engl 2006;45:7942-7948 (Pubitemid 44912747)
13. Hoffmann J, Vitale I, Buchmann B, et al. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 2008;68:5301-5308
14. Alexander EJ, Rosa E, Bolos J, Castaner R. Sagopilone. Drugs Fut 2008;33:496-505.
15. Mbalaviele G, Dunstan CR, Sasaki A, Williams PJ, Mundy GR, Yoneda T. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res 1996;56:4063-4070 (Pubitemid 26284761)
16. Yoneda T. Cellular and molecular basis of preferential metastasis of breast cancer to bone. J Orthop Sci 2000;5:75-81. (Pubitemid 30133795)
17. Everts V, Delaissé JM, Korper W, Niehof A, Vaes G, Beertsen W. Degradation of collagen in the bone-resorbing compartment underlying the osteoclast involves both cysteine-proteinases and matrix metalloproteinases. J Cell Physiol 1992;150:221-231
18. Alatalo SL, Peng Z, Janckila AJ, et al. A novel immunoassay for the determination of tartrate-resistant acid phosphatase 5b from rat serum. J Bone Miner Res 2003;18:134-139 (Pubitemid 36008349)
19. Alexandrova E, Sergieva S, Nikolova V, Danon S. Bone marrow micrometastases as a prognostic factor in early breast cancer patients. J BUON 2003;8:133-137 (Pubitemid 37441400)
20. Colleoni M, O'Neill A, Goldhirsch A, et al. Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol 2000;18:3925-3935
21. Guéritte F. General and recent aspects of the chemistry and structure-activity relationships of taxoids. Curr Pharm Des 2001;7:1229-1249 (Pubitemid 32798806)
22. Rubin H. Cancer cachexia: its correlations and causes. Proc Natl Acad Sci USA 2003;100:5384-5389 (Pubitemid 36542714)
23. Bachmann J, Heiligensetzer M, Krakowski-Roosen H, Büchler MW, Friess H, Martignoni ME. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg 2008;12:1193-1201
24. Kim HL, Han KR, Zisman A, Figlin RA, Belldegrun AS. Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma. J Urol 2004;171:1810-1813 (Pubitemid 38501008)
25. Sakuragi T, Oshita F, Nagashima S, et al. Retrospective analysis of the treatment of patients with small cell lung cancer showing poor performance status. Jpn J Clin Oncol 1996;26:128-133 (Pubitemid 126472308)
26. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588-1594 (Pubitemid 27444031)
27. Jung JI, Kim HH, Park SH, et al. Thoracic manifestations of breast cancer and its therapy. Radiographics 2004;24:1269-1285 (Pubitemid 39329372)
28. Chung YC, Ku CH, Chao TY, Yu JC, Chen MM, Lee SH. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment. Cancer Epidemiol Biomarkers Prev 2006;15:424-428
29. Hall TJ, Jeker H, Schaueblin M. Taxol inhibits osteoclastic bone resorption. Calcif Tissue Int 1995;57:463-465
30. Davis HW, VandenBerg E, Reid MD, Roy-Chaudhury P, Edwards JD. Paclitaxel impairs endothelial cell adhesion but not cytokine-induced cellular adhesion molecule expression. Ann Vasc Surg 2005;19:398-406. (Pubitemid 40884096)
31. Jimi E, Nakamura I, Amano H, et al. Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact. Endocrinology 1996;137:2187-2190 (Pubitemid 26133995)
32. Miyamoto T, Suda T. Differentiation and function of osteoclasts. Keio J Med 2003;52:1-7.
33. Barck KH, Lee WP, Diehl LJ, et al. Quantification of cortical bone loss and repair for therapeutic evaluation in collagen-induced arthritis, by micro-computed tomography and automated image analysis. Arthritis Rheum 2004;50:3377-3386 (Pubitemid 39372016)
34. von Stechow D, Balto K, Stashenko P, Muller R. Three-dimensional quantitation of periradicular bone destruction by micro-computed tomography. J Endod 2003;29:252-256
35. Chao TY, Ho CL, Lee SH, Chen MM, Janckila A, Yam LT. Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients. J Biomed Sci 2004;11:511-516 (Pubitemid 38721035)
36. Coleman RE. Bisphosphonates: clinical experience. Oncologist 2004;9:14-27.
37. Hoffmann J, Fichtner I, Käkönen S-M, Klar U. ZK-EPO, a third-generation epothilone, inhibits breast cancer metastasis. Poster presented at the 97th AACR Annual Meeting, Washington, USA, April 1-5, 2006.
38. Rustin G, Reed N, Jayson G, et al. Phase II trial of the novel epothilone ZK-EPO in patients with platinum-resistant ovarian cancer. Poster 17 presented at the 43rd ASCO Annual Meeting, Chicago, Illinois, USA, June 1-5, 2007.
39. Graff J, Smith DC, Neerukonda L, et al. Phase II study of sagopilone (ZK-EPO) plus prednisone as first-line chemotherapy in patients with metastatic androgen-independent prostate cancer. Poster presented at the 44th ASCO Annual Meeting, Chicago, Illinois, USA, May 30-June 3, 2008.
40. Nguyen TT, Wright JD, Powell MA, et al. Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer. Int J Gynecol Cancer 2008, Epub ahead of print.